Coverage and access intelligence for any drug — keyed to NDC or HCPCS J-code, sliced by payer, state, and tier.
Pending status
This product is in the .dev preview as a pending methodology commitment. It is not presented as a live surface until the source contract, normalization path, refresh cadence, and public-preview limits are ready.
What it is
Formulary Atlas is the market-access companion to PayerPolicy Watch, built on the same pipeline. Where PayerPolicy Watch is a change feed, Formulary Atlas is a queryable register: given a drug, return the coverage landscape across U.S. payers — tier placement, prior-auth burden, step-therapy requirements, quantity limits, site-of-care restrictions, and the date each of those facts last changed.
The product answers four questions pharma market-access teams ask every week. (1) Where did coverage just change for this drug? (2) Which states or payers are formulary-restrictive? (3) What is the PA burden by payer? (4) How does the payer landscape compare to the competing drug in this class?
Sold per drug or per therapeutic area. Pricing scales with coverage breadth requested.
Distribution and join path
Scope: Nationwide; TN Medicaid/Part D slice; Nashville prescriber/hospital impact
Entity graph join: `ndc`/RxCUI, `payer_id`, `npi`, `ccn`, local utilization.
Primary data sources
- Commercial payer formulary publications — Tier placement, UM constraints, quantity limits, site-of-care
- Medicare Part D formulary files — Plan-level coverage for Part D drugs
- State Medicaid PDLs — Preferred Drug List status by state
- PayerPolicy Watch change feed — Same pipeline, queried by drug rather than by code/policy
Buyers
- Pharma market access teams
- Specialty pharmacy network operations
- GPO contracting
- Patient access services groups
Methodology
Coverage is reconstructed from primary payer documents. Each cell carries a 'last verified' date and a link to the underlying source document.
Notify me at launch
Formulary Atlas is pending. Subscribe to The Branmoor Brief to be notified when the source-backed preview is ready.